1. 1 Healthcare Costs and Innovation Capitalizing on DNA-Guided Medicine January 8, 2008 Robert W. Scherrer Vice President and Chief Financial Officer Genomas, Inc. Economic Summit and Outlook Conference

2. 2 Hartford Hospital, IOL, CLP, THOCC, NIH Genomas Partners for DNA-Guided Medicine DNA-Guided Medicine: Cardiology Psychiatry Diabetes Equity Investments Co-owned Intellectual Property and Licensing Clinical Applications Product Prototyping Research Grants $8.8 Million Raised EQUITY FUNDS: $5.3M $500K from Hartford Hospital $500K from Hartford Hospital $500K from Hosp. Central CT $1.2M from Angels $0.6M from Founder/Mgm’t $0.6M from Founder/Mgm’t $2.5M Series C NON-EQUITY FUNDS: $3.5M $200K equipment loan from CT Dept. Economic Dev. $200K equipment loan from CT Dept. Economic Dev. $300K Research Contracts $300K Research Contracts $3.0M NIH SBIR Grants 2006 2004 2005 NIH SBIRStatin/Antipsychotic Phase II & Fast track 2007

3. 3 Overview and Technology Highlights Accomplished execution PRODUCTS PhyzioType™ Systems targeting safety of psychotropic and statin drugs at prototype stage CLIA-certified, licensed lab for initial product support TECHNOLOGY PLATFORM Proven, clinically-based, PhysioGenomics Technology: multi-gene DNA marker ensembles + biostatistical algorithm 5,000 patient repository and database in Cardiometabolic and Psychiatric Medicine Applied successfully to 8 drugs, 2 diets, exercise, MRI INTELLECTUAL PROPERTY 5 Patent applications on PhyzioType Systems and PhysioGenomics Technology 19 Scientific publications $3M SBIR NIH Grants

4. 4 LPH Laboratory of Personalized Health Clinical Lab, High Complexity DNA Typing Licensed by CT Dept of Public Health (CL-0644)Licensed by CT Dept of Public Health (CL-0644) CLIA registeredCLIA registered (ID # 07D1036625 Clinical Laboratory Improvement Amendments) Centers Medicare and Medicaid (CMS) One of the pioneering DNA typing centersOne of the pioneering DNA typing centers In operation since October 2005 CYP 2D6+2C9+2C19, VKORC1 Psych Drugs, Warfarin, Tamoxifen 50 doctors served 300 patients referred 900 DNA Typing tests LABORATORY OF PERSONALIZED HEALTH H LP H

5. 5 Target Markets in Drug Safety Statins and Psychotropics Psychotropic Diabetes Psychotropic Diabetes Diabetic Metabolic Symptoms, 25% $1.4 B settlements by Lilly 2005-2007, War- ning Diabetic risk 2004 6 mil patients 2010 Indications: psychosis bipolar disorder, OCD, major anxiety Zyprexa ®, Risperdal ®, Seroquel ® Zyprexa ®, Risperdal ®, Seroquel ®, $6B mkt Target mkt: 600K patients (10%) on antipsychotics DiMSSIM Statin Induced Myopathy Neuromuscular Side Effects, 20% Baycol ® $1.2B settlement by Bayer 2006, Baycol ® withdrawal 2001 30 mil patients 2010 Indications: post MI, diabetes, CAD, CV risk, aggressive lipid control Lipitor ®, Zocor ®, Crestor ® Lipitor ®, Zocor ®, Crestor ®, $13B mkt Target mkt: 1.5 mil (5%) on statin high- dose > 40 mg/day

6. 6 PhyzioType Systems Medical Device for DNA-Guided Medicine P H Y Z I O T Y P E S Y S T E M S SNP Ensemble Assays P E R S O N A L I Z E D H E A L T H P O R T A L PhysicianInterface BiomathematicalAlgorithms

7. 7 PhyzioType Systems: DiMS Predicting Weight Side Effect, Patient LPH1 Patient LPH1 on Zyprexa ® Clinical Symptoms: Clinical Symptoms: 8 kg weight gain and 8 kg weight gain and abnormal lipids abnormal lipids Referred to LPH and IOL Referred to LPH and IOL for DNA typing of drug for DNA typing of drug metabolism status metabolism status PhyzioType Diagnosis: PhyzioType Diagnosis: Psychotropic DiMS Psychotropic DiMS Risperdal ® is predicted to have the least weight gain for this patient and Zyprexa ® the most. gain for this patient and Zyprexa ® the most. LPH1 is here Zyprexa Risperdal

8. 8 Applications of PhyzioType Systems Diagnostics for DNA-Guided Drug Therapy P H Y Z I O T Y P E S Y S T E M S Side Effect Differential Dx Patient has taken a prescribed drug and manifested side effect PhyzioType used to diagnose likely cause of side effect based on innate genetic factors Allows doctor to clarify etiology of symptoms versus confounding factors (mental status, physical activity, polypharmacy) Side Effect Prevention PhyzioType allows doctor to prescribe drugs according to patient’s individualized drug risk IF SIDE EFFECT RISK IS LOW: Prescribe drug w. safeguard IF SIDE EFFECT RISK IS HIGH: Reduce drug dose Switch to other drugs Proactively monitor/treat

9. 9 DNA-Guided Medicine Envisioning a New Kind of Healthcare “We can see the possibility of health care that is increasingly calibrated to each patient and personally effective for each individual” Michael O. Leavitt Secretary of HHS September 2007

10. 10 Healthcare Costs and Innovatiion DNA-Guided Medicine www.genomas.net